flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Long-term of in obesity and cardiovascular disease in the SELECT Semaglutide in patients with overweight
Description
Improved long-term adherence This is the argument with the strongest practical evidence
Who Is a Good Candidate for Tirzepatide or Semaglutide
As with any medication, potential risks exist, which may include nausea, vomiting, diarrhea, constipation, and abdominal pain
Data Availability All data generated in this study are available within the article and appendices
Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling
